Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | CPB1 | P15086 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2261792 | 1.00 | LMNA (0.52) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL1938713 | 1.00 | LMNA (0.52) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL1938499 | 0.93 | SMN1; SMN2 (0.55) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL7299337 | 0.87 | CPB1 (0.47) | HTTMEN1KMT2AGAACPB1 | |
| SCHEMBL12812726 | 0.82 | KMT2A (0.64) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL19083306 | 0.81 | LMNA (0.53) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL12812906 | 0.81 | LMNA (0.56) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL7296884 | 0.80 | F10 (0.48) | SMN1; SMN2HTTMEN1KMT2AGAA | |
| SCHEMBL29017563 | 0.79 | TSHR (0.49) | GAACPB1ALDH1A1HTR2CTSHR | |
| SCHEMBL29017564 | 0.79 | TSHR (0.49) | GAACPB1ALDH1A1HTR2CTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER REC TECH LTD (GB) | 2014-11-27 | — | — | US | disclosed |
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER REC TECH LTD (GB) | 2014-11-27 | — | — | US | disclosed |
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER REC TECH LTD (GB) | 2014-11-27 | — | — | US | disclosed |
| US-8778925-B2 | Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8778925-B2 | Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8778925-B2 | Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED | 2011-08-04 | — | — | US | disclosed |
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED | 2011-08-04 | — | — | US | disclosed |
| EP-2331523-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010041054-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010041054-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | WNT1, CTNNB1, WNT3 | LMNA 3945/4885SMN1; SMN2 4623/4885HTT 4535/4885 |
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | WNT1, CTNNB1, WNT3 | LMNA 3945/4885SMN1; SMN2 4623/4885HTT 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.